ReviewFrontiers in immunology2025
Lymphatic dissemination of HPV-positive oropharyngeal squamous cell carcinoma: underlying mechanisms and treatment innovations.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plant Bioactive Constituents and Their Potential Benefits in HPV-Positive Oropharyngeal Squamous Cell Carcinoma-A Narrative Review.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers, with its rising incidence strongly linked to human papillomavirus (HPV) infection, particularly HPV16. HPV-induced OPSCC (HPV-OPSCC) exhibits distinct biological behaviors, including a high propensity for early lymphatic metastasis, occurring in most of cases, often presenting as cystic lymph node changes. The rising incidence of HPV-positive OPSCC is associated with specific mechanisms, particularly the characteristic biological behaviors driven by the E6/E7 oncoproteins: E7 disrupts cell cycle control by degrading pRb protein, while E6 inhibits apoptotic pathways through ubiquitination-mediated degradation of p53. Despite advances in treatment, HPV-OPSCC poses unique challenges due to its complex tumor microenvironment and immune interactions. Tertiary lymphoid structures (TLS) within the tumor microenvironment play a critical role in modulating anti-tumor immunity, correlating with improved clinical outcomes. Recent advances in immunotherapy, such as immune checkpoint inhibitors and HPV-specific vaccines, have shown promise in enhancing patient survival. This review explores the mechanisms of HPV-driven carcinogenesis, the clinical and molecular features of lymphatic metastasis, and the emerging role of TLS and immunotherapeutic strategies in HPV-OPSCC. By analyzing existing evidence, this review seeks to clarify the distinct biological features of HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) and guide the development of novel treatment strategies aimed at enhancing clinical outcomes for patients. (OPSCC).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.